Quadracel
Details for Quadracel vaccine and its components.
Sponsor:
Sanofi Pasteur Pty Ltd
Administration route:
Intramuscular injection
Vaccine group:
Combination vaccines
Registered for primary immunisation in infants aged 2–12 months and as a booster in children aged 15 months to 6 years.
DTPa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine
Each 0.5 mL monodose vial contains:
- ≥30 IU diphtheria toxoid
- ≥40 IU tetanus toxoid
- 20 µg pertussis toxoid
- 20 µg filamentous haemagglutinin
- 3 µg pertactin
- 5 µg pertussis fimbriae types 2 and 3
- 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
- 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
- 32 D-antigen units inactivated poliovirus type 3 (Saukett)
- 1.5 mg aluminium phosphate
- ≤50 ng bovine serum albumin
- 0.6% v/v phenoxyethanol
Also contains traces of:
- formaldehyde
- glutaraldehyde
- polysorbate 80
- polymyxin
- neomycin
For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Definitions
- DTPa
- diphtheria-tetanus-acellular pertussis vaccine
- IPV
- inactivated poliomyelitis vaccine
- IU
- international units
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/quadracel.